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A B S T R A C T   
Abstract.introduction.and.importance: Autosomal dominant hypophosphatemic rickets is the most common form of 
rare rickets, commonly manifests in children but sometimes the condition remains undiagnosed due to lack of 
knowledge &/or awareness of treating physicians or surgeons. 
Case presentation: We describe a case of 43 years old female with multiple fragility fractures since childhood, 
corrected surgically but never investigated. She had stunted growth, bowing deformities and loss of teeth. 
Clinical discussion: A detailed history and examination along with metabolic and genetic work up mounted the 
diagnosis of X linked hypophosphatemic osteomalacia. The pathophysiology involves the mutation or the loss of 
the phosphate regulating gene on PHEX, that causes reduced mineralization of bones and teeth. 
Conclusion: Diagnostic delay in this patient resulted in increased disabilities affecting her mobility and lif estyle.   
1. Introduction 
Inherited metabolic diseases (IMDs) of bone are rare, with less than 1 
per 200,000 incidence. Not only they have a heterogenous etiology, 
there is a wide variation in onset and disease severity [1]. Recently 
significant advances are made in understanding the underlying genetic 
and molecular pathways in the pathogenesis of rare bone diseases with 
new gene discovery and expansion of the classification system [1]. 
Almost 400 different forms of skeletal dysplasias have been described so 
far and the number continues to increase with advancement in molec-
ular pathology. Worldwide the diagnostic capability and provision of 
accurate genetic counseling has been greatly improved. Increase 
comprehension of molecular pathways has also resulted in increase 
availability of therapeutic options for management of many disorders 
like osteogenesis imperfecta (OI), X-linked hypophosphatemia (XLH), 
primary hypoparathyroidism, osteopetrosis and hypophosphatasia. 
There is evolving interest in gene manipulation therapy too, to provide 
curative options for these often lethal disorders [2]. However, knowl-
edge and awareness of these disorders among clinicians remains a 
diagnostic challenge because of their rarity and wide variety. But once 
diagnosed accurately patients may be treated appropriately, bone ab-
normalities prevented, emotional and financial devastation of the pa-
tients and their families may be compensated to some extent. 
We describe a case presenting as adult with multiple bone de-
formities from childhood and treated surgically without diagnosis.This 
work is inline with the SCARE criteria 2020 [3,4]. (ref:scare criteria 
2020) 
1.1. Case presentation 
A forty three years old, wheelchair-bound female presented to the 
metabolic bone clinic of Aga Khan University Hospital with short stature 
and grossly deformed bones of limbs and vertebrae. She achieved all 
milestones on time in childhood. She belonged to a financially sound 
family. The patient successfully passed her middle school and could not 
continue further studies because of her illness. There was no family 
history of having similar disorder and all of her siblings were in good 
state of health. 
She developed low trauma fracture for the first time at eight years of 
age and was treated surgically. She had multiple low trauma fractures 
since childhood and surgical corrections with placement of rods were 
performed on multiple occasions. Her disability continued to increase 
with time and she was unable to walk and became wheelchair-bound. 
She lost all her teeth and was wearing dental prosthesis when exam-
ined in clinic. She also had a history of low trauma hip fracture one year 
back. She developed hypertension at the age of forty one years for which 
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she was taking the combination of valsartan/hydrochlorothiazide 160/ 
25mg. 
On examination, the patient was short in height 4ft, with extreme 
bowing deformities involving leg, arms and back. She has light blue 
sclera, artificial teeth with clear oral hygiene. She had multiple scars of 
previous surgeries on arms and legs. 
Results of the few biochemical investigations available with the pa-
tient included a normal complete blood count and lipid profile, serum 
calcium of 9.4 mg/dl, a serum 25 hydroxy vitamin D (25OHD) of 21.9 
ng/ml, blood urea nitrogen and creatinine of 16 mg/dl and 0.8 mg/dl 
respectively. She was prescribed calcium supplements, and injection 
zoledronic acid. On her inquiry from physician, she was told that she had 
low bone mineral density (BMD) on DXA and was also provided with the 
diagnosis of Osteogenesis imperfecta few years back. 
We advised for a complete metabolic workup. Her biochemical 
investigation showed serum calcium 9.1 mg/dl (while on calcium sup-
plement), serum phosphorus 2.2 mg/dl, serum 25OHD 27 ng/dl,1,25 
(OH)D 54pg/dl, iPTH 176pg/dl. 24 hours urinary chemistry showed the 
following: protein 78.4 mg/dl, phosphorus 275.5, potassium 18.26, so-
dium 69.49, creatinine 0.34mmol/24hrs and creatinine clearance 
73.7ml/min. The patient was identified to have low phosphorus and 
high PTH with optimal vitamin D levels. A preliminary diagnosis of 
hypophosphatemic osteomalacia was made and genetic consult was 
sought. Sample for genetic testing of the following hypophosphatemic 
gene panel ALPL, CLCNS, CYP2787, CYP2R1, DMPI, ENPPI, FAH, 
FAM20C, FGF23, FGFR1, PHEX, SLC34A3, VDR was sent to Invitae 
Medical Genetic Testing Expert Trust in Sanfransisco California. A 
pathogenic variant c.871C > T ((p. Arg291) was identified on PHEX 
gene confirming the diagnosis of X linked hypophosphatemic rickets. 
She was started with potassium phosphate in divided doses and 
alfacalcidiol once daily. She has been counseled for XLH in detail about 
the disease and its inheritance, she was provided with instructions to 
avoid fall. On follow up after four weeks time, her pain greatly improved 
and she was advised to repeat serum calcium, serum phosphate and 
plasma PTH. 
2. Discussion 
The diagnosis of many rare bone diseases has been limited by 
physician access to the most up-to-date information about availability of 
diagnostic tests and diagnostic criteria for these rare diseases. A variety 
of factors including lack of knowledge and/or experience, lack of re-
sources, or failure to follow recommendations may interfere with a 
physician’s use of effective diagnostic techniques, preventive measures, 
and timely managements. Although genetic tests are crucial to the 
diagnosis of many rare bone diseases [5] the ordering of a specific test or 
set of tests typically depends on a clinician’s evaluation and ability to 
recognize clues pointing to conditions for which genetic testing may be 
warranted. However, availability of genetic testing in Pakistan is only 
available at few places, but the initial stages of diagnosis still depend on 
classic clinical practices including patient history, physical examination, 
use of laboratory investigations and application of clinical knowledge 
and reasoning skills. One dilemma for clinicians and patients is that 
many rare diseases have symptoms that accompany a number of com-
mon conditions and laboratory results may or may not be definitive. 
Physicians may consider common conditions that are consistent with the 
available information before considering rare conditions. 
Rickets and osteomalacia represents a group of diseases of divergent 
causes, characterized by a defect in matrix mineralization [6]. The cause 
is any condition resulting in inadequate calcium or phosphate miner-
alization of bone osteoid resulting in either hypocalcemia or hypo-
phosphatemia. Phosphate being sufficiently abundant in natural foods 
dietary phosphate deficiency is unlikely to develop except under con-
ditions of extreme starvation. Phosphate homeostasis and plasma 
phosphate concentration depends primarily on the renal tubular trans-
port of phosphate and disorders of renal phosphate wasting are the most 
common hereditary forms of rickets and osteomalacia in western 
countries [7]. Renal hypophosphatemia can be calculated by measuring 
the tubular maximum for phosphate reabsorption (TMP/GFR) by 
routine biochemical investigations[8]. Reduced TMP/GFR with low 
serum phosphorus points is suggestive of renal phosphate wasting. In 
addition low or normal alkaline phosphatase, normal parathyroid levels 
and normal or reduced calcium levels would further support hypo-
phosphatemic rickets/osteomalacia. Table 1 shows the types of hypo-
phosphatemic rickets/osteomalacia encountered in clinical practice 
with distinct pathophysiological basis, gene affected and different ap-
proaches to treatment with subtle difference in the biochemical diag-
nosis by routine chemistries. Hence, genetic testing plays an important 
role in differentiating amongst the inherited hypophosphatemic condi-
tions. With increase availability of therapeutic options; it is important to 
differentiate between the various hypophosphatemic conditions [9]. For 
example ADHR/O has similar manifestations, with clinical rickets, and 
inappropriately low levels of 1,25 (OH)2 D. The cause is mutations of 
FGF23 gene that result in resistance to degradation, and accumulation of 
high circulating levels of FGF23, and subsequent phosphaturia. The 
spectrum of disease in ADHR/O includes not only the classic presenta-
tion with early onset of hypophosphatemia and rickets, but also includes 
delayed onset of clinically evident disease [9]. in which patients present 
after puberty with hypophosphatemia at an age ranging from 14.5 to 45 
years with complaints of bone pains, weakness and fatigue without 
having histories of rickets or lower extremity deformities as a child. 
Econs in 1997 suggested that apparently individuals who presented as 
adults were able to compensate for genetic defects initially but later lost 
the ability to compensate [10]. Treatment involves correction of ab-
normalities caand administration of calcitriol and phosphate. However, 
there is limited data on treatment of ADHR/O compare to XLH. Simi-
larly, in HHRH, the accurate diagnosis has important therapeutic im-
plications. Unlike XLH & ADHR/O, phosphate supplementation alone 
can bring in remission wheras addition of vitamin D can create com-
plications such as hypercalcemia, nephrocalcinosis and renal damage. 
XLH is rare but commonest among other inherited forms of rickets. 
Most commonly occurs in children (1 in 20,000) but often misdiagnosed 
in childhood and may manifest as osteomalacia in adults [7]. The 
pathophysiology involves the loss of phosphate regulating gene with the 
homology to endopeptidase located on the X chromosome (PHEX) [11, 
12]. PHEX enzymes are involved in phosphate homeostasis through 
regulation of a protein called Fibroblasr growth factor (FGF23), secretd 
by bone osteoclasts and osteoblasts [11]. FGF 23 activates the renal 
KLOTHO receptors 1 that inhibit the phosphate reabsorption by down-
regulation of Napi2a and Napi2c expressions and sodium-phosphate 
co-transporter in the proximal renal tubules resulting in hypo-
phosphatemia. FGF23 can reduce the regulation of CYP271B (that en-
codes 25OHD-1@-Hydroxylase) and upgrade the control of CYP24A1 
(that encode 24-Hydroxylase) [13]. As a result there is lower level of 1, 
25OH2D due to decreased synthesis and increased catabolism. FGF23 is 
involved in several phosphate wasting disorders including Autosomal 
dominant hypophosphatemic rickets/osteomalacia (ADHR/O), onco-
genic hypophosphatemic osteomalacia (OHO), McCune-Albright syn-
drome (MAS), fibrous dysplasia of bone (FD), and humoral 
hypercalemia of malignancy [9]. 
In Pakistan the first case of hypophosphatemic rickets was reported 
in 2004 diagnosis were made on the basis of family history and lab in-
vestigations. Now we report the second case of XLH, confirmed on ge-
netic testing.This case report provides a new doorway to the 
investigations for physicians/clinicians. It is a possibility that there is 
underreporting of such cases. In the past this patient was given the 
diagnosis of osteogenesis imperfecta which is associated with type 1 
collagen deficiency. While fragility fractures are common in both, the 
biochemical investigations are within normal limits in OI in contrast to 
XLH. Hence, it is important to screen with appropriate lab investigation. 
Patient was councelled regarding the XLRH and prescribed with calcium 
phospahtes and vitamin D supplements. 




CLINICAL biochemical, molecular and treatment in different hypophosphatemic rickets/osteomalacia.   




Vitamin d resistent hypophosphatemic 
osteomalacia 
Mc Cune albright syndrome (MAS) Fibrodysplasia ossificans 
progressiva (FOP) 
BLOODS S. CALCIUM Normal Normal Decreased Normal/Increased Normal 
S. PHOSPHATE Decreased Decreased Decreased Decreased Decreased 
Alkaline 
phosphatase 
Increased/Normal Increased Increased Increased Increased 
25 OHD Normal Normal Normal Normal Normal 
1,25 (OH)D Normal/Decreased Normal/Decreased Normal Normal Normal 
PTH Normal/Increased Normal/Increased Increased Increased Increased 
URINE URINARY 
CALCIUM 
Normal Normal Increased Normal Normal 
URINARY 
PHOSPHATE 
Increased Increased Increased Increased Increased 





7–8 years 5–7 years 
14.5–45 years 
6–7 years 15 -20 YARS 13–20s 
BONE 
DEFORMITIES 
Short stature, bowing of legs, 




Muscle weakness fractures 
Leg bone deformities, Cranial deformities, 
frontal bossing. 
Not apparent bony deformities. 
CAFÉ-‘aulet spots, Mosaic like skin 
pigmentation 
Endocrinopathies. 
Bone pain, Heterotopic ossification 
of soft tissues, immobility, swelling 
of femur, tibia, ribs and skull 
DENTAL 
DEFORMITIES 
Dental carries, Tooth 
deformities 
Tooth access Delayed tooth eruption Swelling of the jaws. Fibrous lesion of 
the jaws  
MOLECULAR 
PATHWAYS  
PHEX Mutation on 22.2 and 
22.1 on X chromosome 
Heterozygous Point mutation 
on amino acid 176 or 179 at 
FGF23 
Genetic defect in conversion of 25 
hydroxyvitaminD2 to 1,25 dihydroxy 
vitamin D and increased levels of FGF 23. 
Embryonic postzygotic activation in 
GNAS 1 gene encoding cAMP 
pathways associated G protein and 
Gas. 
Mutation on ACVR1/ALK2 gene on 
chromosome 2q 24 
MAIN MODE OF 
TREATMENT  
Vitamin D supplements, oral 
phosphate supplements, 
Burosumab 
Oral Phosphate supplements 
and calcitriol 
Oral phosphate and calcitriol 
supplements 
Bisphosphonates, Strengthening 
exercises, Surgical interventions. 
Glucocorticoids to avoid the 
infections, surgical intervention  
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One relatively newer drug option is that of Cinacalcet; which is a 
calcimimmatics and regulates the parathyroid hormone by decreasing 
the extracellular calcium and reducing the parathyroid levels[14]. 
Recently, Burosumab (Crysvita, Ultragenyx) has been approved by FDA 
for the treatment of hypophosphatemic rickets and recommended as the 
first line of treatment for the adults and children older then 1 year 
suffering from hypophosphatemic rickets. Burosumab is an antibody 
that binds the FGF23 in XLH patients normalizing the phosphorus levels 
and improving the bone mineralization[15]. 
International data shows that early diagnosis and improved treat-
ment for a number of bone disorders have increased the number of 
children who survive to adulthood with improved quality of life. Genetic 
counseling is also important step for individuals and families following 
the diagnosis to help them better understand the disorder, consider their 
options, and plan for the future. Family members may be advised about 
their options to be tested. Lack of availability and access to genetic 
counsellors in Pakistan is one negelcted area. There is a need to educate 
and assist physicians about the rare bone diseases in Pakistan for 
improving the provision of care. Need for development of local clinical 
practice guidelines, continuing medical education activities, develop-
ment of centers of excellence for rare skeletal disease and/or establish-
ing referral centers is needed in a resource limite country like Pakistan. 
The centers of excellence can also provide a base for research and may 
act as nidus for establishment of a network of accredited care centers to 
promote multidisciplinary, multicenter, collaborative research and 
more resources for translational research. In addition, centers can bring 
together comprehensive expertise and resources to address patient 
needs, and to monitor the care provided to the patient suffering from 
rare skeletal disorders. 
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